Mode
Text Size
Log in / Sign up
N/A N=193

The Clinical Utility of Overtube Use at the Time of Endoscopy

Small Bowel Visualization

Enrolled (actual)
193
Serious AEs
4.2%
Results posted
Apr 2014
Primary outcome: Primary: Number of Patients With Persistent or Recurrent Bleeding — 16 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
overtube use during enteroscopy (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Florida
Primary completion
Oct 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Persistent or Recurrent Bleeding
16

Summary

Endoscopy has become a vital part of the gastroenterologist's evaluation and treatment of disorders involving the gastrointestinal (GI) tract. The small bowel is an area of the GI tract, which can prove difficult to visualize during an endoscopy specifically designed to evaluate it, termed enteroscopy. Thus, the FDA has approved overtubes, such as the Endo-Ease® spiral overtube (Spirus Medical, Inc.) or EnteroPro® balloon overtube (Olympus Medical, Inc.), to facilitate passage of the endoscope through the GI tract. The aims of the study are to evaluate the efficiency of an overtube system for visualization of small bowel. The hypothesis is that this will permit more complete and efficient evaluation of the small intestine.

Eligibility Criteria

Inclusion Criteria

  • Subjects ≥ 18 years.
  • Have an indication for enteroscopy as determined by the patient's physicians. These indications include, but are not limited to, obscure gastrointestinal bleeding, malabsorption, suspected small bowel tumor, small bowel strictures, small bowel ulceration, and abnormal imaging of the small bowel.
  • Scheduled to undergo enteroscopy at the University of Florida, Gainesville, Florida, as medically indicated.
  • Subject must be able to give informed consent.

Exclusion Criteria

  • Platelets 1.6.
  • NSAIDS within 48 hours of procedure.
  • Pregnancy.
  • Esophageal stricture.
  • Inability to give informed consent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00861263). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search